Rituximab treatment of adults with primary focal segmental glomerulosclerosis

To evaluate the efficacy and safety of rituximab (RTX) in the treatment of primary focal segmental glomerulosclerosis (FSGS) in adults. The clinical data of patients with primary FSGS who received RTX treatment in the First Affiliated Hospital of Zhengzhou University were analyzed retrospectively. T...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2023-04, Vol.13 (1), p.6740-6740, Article 6740
Main Authors: Wang, Liuwei, Yu, Lu, Wang, Yulin, Guo, Yanhong, Zhai, Zihan, Tang, Lin
Format: Article
Language:English
Subjects:
631/250/1619/40/1906
692/699/1585/2759/1523
Adult
End-stage renal disease
Glomerulosclerosis, Focal Segmental - complications
Glucocorticoids
Glucocorticoids - therapeutic use
Humanities and Social Sciences
Humans
Immunosuppressive agents
Immunotherapy
Kidney diseases
Lymphocytes B
Male
Monoclonal antibodies
multidisciplinary
Nephrotic syndrome
Nephrotic Syndrome - complications
Nephrotic Syndrome - drug therapy
Patients
Peripheral blood
Recurrence
Remission
Remission (Medicine)
Retrospective Studies
Rituximab
Rituximab - adverse effects
Science
Science (multidisciplinary)
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c492t-4b316d57293024b95550da6c594417cb0c6f3f39774996d969590bc8dd12bf0d3
container_end_page 6740
container_issue 1
container_start_page 6740
container_title Scientific reports
container_volume 13
creator Wang, Liuwei
Yu, Lu
Wang, Yulin
Guo, Yanhong
Zhai, Zihan
Tang, Lin
description To evaluate the efficacy and safety of rituximab (RTX) in the treatment of primary focal segmental glomerulosclerosis (FSGS) in adults. The clinical data of patients with primary FSGS who received RTX treatment in the First Affiliated Hospital of Zhengzhou University were analyzed retrospectively. The selected patients received RTX twice or four times, with a single dose of 375 mg/m 2 , and the interval between two times of administration of RTX was 2–4 weeks. The treatment target is to achieve the clearance of B cells (peripheral blood B cell count 
doi_str_mv 10.1038/s41598-023-33678-y
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ad47359d97f6436bad438f7e1dcc6f4f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ad47359d97f6436bad438f7e1dcc6f4f</doaj_id><sourcerecordid>2814523665</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-4b316d57293024b95550da6c594417cb0c6f3f39774996d969590bc8dd12bf0d3</originalsourceid><addsrcrecordid>eNp9kctu1TAQhi0EolXpC7BAkdiwCfjueIVQxaVSERKCteX4kuYoiYvtFM7bM20OpWWBN77MN__M-EfoOcGvCWbdm8KJ0F2LKWsZk6pr94_QMcVctJRR-vje-QidlrLDsATVnOin6Igp0gmm8DH6_HWs669xtn1Tc7B1DkttUmysX6damp9jvWyuMsTzvonJ2akpYbiB4DRMaQ55nVJxU8ipjOUZehLtVMLpYT9B3z-8_3b2qb348vH87N1F67imteU9I9ILRTXDlPdaCIG9lU5ozolyPXYyssi0Ulxr6bXUQuPedd4T2kfs2Qk633R9sjtz6M8kO5rbh5QHY3MdoS1jPVdMaK9VlJzJHu6siyoQ76AKj6D1dtO6Wvs5eAezZTs9EH0YWcZLM6RrQzBhmAgKCq8OCjn9WEOpZh6LC9Nkl5DWYmhHOGBSCkBf_oPu0poX-CugsFCKQo9A0Y1y8Kslh3jXDcHmxn2zuW_AfXPrvtlD0ov7c9yl_PEaALYBBULLEPLf2v-R_Q3labuv</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2805772436</pqid></control><display><type>article</type><title>Rituximab treatment of adults with primary focal segmental glomerulosclerosis</title><source>PubMed (Medline)</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Wang, Liuwei ; Yu, Lu ; Wang, Yulin ; Guo, Yanhong ; Zhai, Zihan ; Tang, Lin</creator><creatorcontrib>Wang, Liuwei ; Yu, Lu ; Wang, Yulin ; Guo, Yanhong ; Zhai, Zihan ; Tang, Lin</creatorcontrib><description>To evaluate the efficacy and safety of rituximab (RTX) in the treatment of primary focal segmental glomerulosclerosis (FSGS) in adults. The clinical data of patients with primary FSGS who received RTX treatment in the First Affiliated Hospital of Zhengzhou University were analyzed retrospectively. The selected patients received RTX twice or four times, with a single dose of 375 mg/m 2 , and the interval between two times of administration of RTX was 2–4 weeks. The treatment target is to achieve the clearance of B cells (peripheral blood B cell count &lt; 5/μl). The primary outcome measures were remission and recurrence of renal disease, and the secondary outcome measures were adverse events and renal outcomes. A total of 14 FSGS patients were included, including 12 males, 9 with glucocorticoid-dependent or frequently relapsing nephrotic syndrome, and 3 with newly diagnosed nephrotic syndrome. After RTX treatment, 7 patients with glucocorticoid-dependent/recurrent nephrotic syndrome were completely relieved. At 6 months of follow-up, glucocorticoids were discontinued in all patients except 1 patient. The other 5 patients achieved partial remission (PR), of which 1 patient relapsed after PR, and 1 initial patient achieved complete remission. One patient progressed to end-stage renal disease (ESRD) after 4 months of follow-up. RTX in the treatment of adult glucocorticoid-dependent/relapsing FSGS can reduce the risk of recurrence and help to decline or discontinue the use of glucocorticoid and immunosuppressants.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-023-33678-y</identifier><identifier>PMID: 37185370</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/1619/40/1906 ; 692/699/1585/2759/1523 ; Adult ; End-stage renal disease ; Glomerulosclerosis, Focal Segmental - complications ; Glucocorticoids ; Glucocorticoids - therapeutic use ; Humanities and Social Sciences ; Humans ; Immunosuppressive agents ; Immunotherapy ; Kidney diseases ; Lymphocytes B ; Male ; Monoclonal antibodies ; multidisciplinary ; Nephrotic syndrome ; Nephrotic Syndrome - complications ; Nephrotic Syndrome - drug therapy ; Patients ; Peripheral blood ; Recurrence ; Remission ; Remission (Medicine) ; Retrospective Studies ; Rituximab ; Rituximab - adverse effects ; Science ; Science (multidisciplinary) ; Treatment Outcome</subject><ispartof>Scientific reports, 2023-04, Vol.13 (1), p.6740-6740, Article 6740</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c492t-4b316d57293024b95550da6c594417cb0c6f3f39774996d969590bc8dd12bf0d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2805772436/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2805772436?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37185370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Liuwei</creatorcontrib><creatorcontrib>Yu, Lu</creatorcontrib><creatorcontrib>Wang, Yulin</creatorcontrib><creatorcontrib>Guo, Yanhong</creatorcontrib><creatorcontrib>Zhai, Zihan</creatorcontrib><creatorcontrib>Tang, Lin</creatorcontrib><title>Rituximab treatment of adults with primary focal segmental glomerulosclerosis</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>To evaluate the efficacy and safety of rituximab (RTX) in the treatment of primary focal segmental glomerulosclerosis (FSGS) in adults. The clinical data of patients with primary FSGS who received RTX treatment in the First Affiliated Hospital of Zhengzhou University were analyzed retrospectively. The selected patients received RTX twice or four times, with a single dose of 375 mg/m 2 , and the interval between two times of administration of RTX was 2–4 weeks. The treatment target is to achieve the clearance of B cells (peripheral blood B cell count &lt; 5/μl). The primary outcome measures were remission and recurrence of renal disease, and the secondary outcome measures were adverse events and renal outcomes. A total of 14 FSGS patients were included, including 12 males, 9 with glucocorticoid-dependent or frequently relapsing nephrotic syndrome, and 3 with newly diagnosed nephrotic syndrome. After RTX treatment, 7 patients with glucocorticoid-dependent/recurrent nephrotic syndrome were completely relieved. At 6 months of follow-up, glucocorticoids were discontinued in all patients except 1 patient. The other 5 patients achieved partial remission (PR), of which 1 patient relapsed after PR, and 1 initial patient achieved complete remission. One patient progressed to end-stage renal disease (ESRD) after 4 months of follow-up. RTX in the treatment of adult glucocorticoid-dependent/relapsing FSGS can reduce the risk of recurrence and help to decline or discontinue the use of glucocorticoid and immunosuppressants.</description><subject>631/250/1619/40/1906</subject><subject>692/699/1585/2759/1523</subject><subject>Adult</subject><subject>End-stage renal disease</subject><subject>Glomerulosclerosis, Focal Segmental - complications</subject><subject>Glucocorticoids</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>Immunotherapy</subject><subject>Kidney diseases</subject><subject>Lymphocytes B</subject><subject>Male</subject><subject>Monoclonal antibodies</subject><subject>multidisciplinary</subject><subject>Nephrotic syndrome</subject><subject>Nephrotic Syndrome - complications</subject><subject>Nephrotic Syndrome - drug therapy</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Recurrence</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Rituximab - adverse effects</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Treatment Outcome</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kctu1TAQhi0EolXpC7BAkdiwCfjueIVQxaVSERKCteX4kuYoiYvtFM7bM20OpWWBN77MN__M-EfoOcGvCWbdm8KJ0F2LKWsZk6pr94_QMcVctJRR-vje-QidlrLDsATVnOin6Igp0gmm8DH6_HWs669xtn1Tc7B1DkttUmysX6damp9jvWyuMsTzvonJ2akpYbiB4DRMaQ55nVJxU8ipjOUZehLtVMLpYT9B3z-8_3b2qb348vH87N1F67imteU9I9ILRTXDlPdaCIG9lU5ozolyPXYyssi0Ulxr6bXUQuPedd4T2kfs2Qk633R9sjtz6M8kO5rbh5QHY3MdoS1jPVdMaK9VlJzJHu6siyoQ76AKj6D1dtO6Wvs5eAezZTs9EH0YWcZLM6RrQzBhmAgKCq8OCjn9WEOpZh6LC9Nkl5DWYmhHOGBSCkBf_oPu0poX-CugsFCKQo9A0Y1y8Kslh3jXDcHmxn2zuW_AfXPrvtlD0ov7c9yl_PEaALYBBULLEPLf2v-R_Q3labuv</recordid><startdate>20230425</startdate><enddate>20230425</enddate><creator>Wang, Liuwei</creator><creator>Yu, Lu</creator><creator>Wang, Yulin</creator><creator>Guo, Yanhong</creator><creator>Zhai, Zihan</creator><creator>Tang, Lin</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230425</creationdate><title>Rituximab treatment of adults with primary focal segmental glomerulosclerosis</title><author>Wang, Liuwei ; Yu, Lu ; Wang, Yulin ; Guo, Yanhong ; Zhai, Zihan ; Tang, Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-4b316d57293024b95550da6c594417cb0c6f3f39774996d969590bc8dd12bf0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>631/250/1619/40/1906</topic><topic>692/699/1585/2759/1523</topic><topic>Adult</topic><topic>End-stage renal disease</topic><topic>Glomerulosclerosis, Focal Segmental - complications</topic><topic>Glucocorticoids</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>Immunotherapy</topic><topic>Kidney diseases</topic><topic>Lymphocytes B</topic><topic>Male</topic><topic>Monoclonal antibodies</topic><topic>multidisciplinary</topic><topic>Nephrotic syndrome</topic><topic>Nephrotic Syndrome - complications</topic><topic>Nephrotic Syndrome - drug therapy</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Recurrence</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Rituximab - adverse effects</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Liuwei</creatorcontrib><creatorcontrib>Yu, Lu</creatorcontrib><creatorcontrib>Wang, Yulin</creatorcontrib><creatorcontrib>Guo, Yanhong</creatorcontrib><creatorcontrib>Zhai, Zihan</creatorcontrib><creatorcontrib>Tang, Lin</creatorcontrib><collection>Springer Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Liuwei</au><au>Yu, Lu</au><au>Wang, Yulin</au><au>Guo, Yanhong</au><au>Zhai, Zihan</au><au>Tang, Lin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rituximab treatment of adults with primary focal segmental glomerulosclerosis</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2023-04-25</date><risdate>2023</risdate><volume>13</volume><issue>1</issue><spage>6740</spage><epage>6740</epage><pages>6740-6740</pages><artnum>6740</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>To evaluate the efficacy and safety of rituximab (RTX) in the treatment of primary focal segmental glomerulosclerosis (FSGS) in adults. The clinical data of patients with primary FSGS who received RTX treatment in the First Affiliated Hospital of Zhengzhou University were analyzed retrospectively. The selected patients received RTX twice or four times, with a single dose of 375 mg/m 2 , and the interval between two times of administration of RTX was 2–4 weeks. The treatment target is to achieve the clearance of B cells (peripheral blood B cell count &lt; 5/μl). The primary outcome measures were remission and recurrence of renal disease, and the secondary outcome measures were adverse events and renal outcomes. A total of 14 FSGS patients were included, including 12 males, 9 with glucocorticoid-dependent or frequently relapsing nephrotic syndrome, and 3 with newly diagnosed nephrotic syndrome. After RTX treatment, 7 patients with glucocorticoid-dependent/recurrent nephrotic syndrome were completely relieved. At 6 months of follow-up, glucocorticoids were discontinued in all patients except 1 patient. The other 5 patients achieved partial remission (PR), of which 1 patient relapsed after PR, and 1 initial patient achieved complete remission. One patient progressed to end-stage renal disease (ESRD) after 4 months of follow-up. RTX in the treatment of adult glucocorticoid-dependent/relapsing FSGS can reduce the risk of recurrence and help to decline or discontinue the use of glucocorticoid and immunosuppressants.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>37185370</pmid><doi>10.1038/s41598-023-33678-y</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2023-04, Vol.13 (1), p.6740-6740, Article 6740
issn 2045-2322
2045-2322
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ad47359d97f6436bad438f7e1dcc6f4f
source PubMed (Medline); Publicly Available Content Database (Proquest) (PQ_SDU_P3); Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access
subjects 631/250/1619/40/1906
692/699/1585/2759/1523
Adult
End-stage renal disease
Glomerulosclerosis, Focal Segmental - complications
Glucocorticoids
Glucocorticoids - therapeutic use
Humanities and Social Sciences
Humans
Immunosuppressive agents
Immunotherapy
Kidney diseases
Lymphocytes B
Male
Monoclonal antibodies
multidisciplinary
Nephrotic syndrome
Nephrotic Syndrome - complications
Nephrotic Syndrome - drug therapy
Patients
Peripheral blood
Recurrence
Remission
Remission (Medicine)
Retrospective Studies
Rituximab
Rituximab - adverse effects
Science
Science (multidisciplinary)
Treatment Outcome
title Rituximab treatment of adults with primary focal segmental glomerulosclerosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T08%3A35%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rituximab%20treatment%20of%20adults%20with%20primary%20focal%20segmental%20glomerulosclerosis&rft.jtitle=Scientific%20reports&rft.au=Wang,%20Liuwei&rft.date=2023-04-25&rft.volume=13&rft.issue=1&rft.spage=6740&rft.epage=6740&rft.pages=6740-6740&rft.artnum=6740&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-023-33678-y&rft_dat=%3Cproquest_doaj_%3E2814523665%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c492t-4b316d57293024b95550da6c594417cb0c6f3f39774996d969590bc8dd12bf0d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2805772436&rft_id=info:pmid/37185370&rfr_iscdi=true